Intuitive Surgical stock price target raised to $610 from $595 at Piper Sandler

Investing.com - Piper Sandler raised its price target on Intuitive Surgical (NASDAQ:ISRG) to $610 from $595 on Wednesday, while maintaining an Overweight rating on the surgical robotics company. The medical technology giant, currently valued at $165.88 billion, trades at a P/E ratio of 64.8x, reflecting high growth expectations. InvestingPro analysis indicates the stock is trading above its Fair Value.

The price target increase follows Intuitive Surgical’s third-quarter financial results, which Piper Sandler described as "across-the-board robust" with strong performance in both top and bottom lines, as well as key operating metrics including procedure volumes and system placements. The company’s impressive 20.77% revenue growth and healthy gross margin of 66.61% support this assessment. InvestingPro data reveals 11 additional key insights about ISRG’s performance.

Intuitive Surgical also raised its full-year 2025 procedure growth guidance to 17-17.5% from its previous forecast of 15.5-17%, and increased its gross margin guidance to 67-67.5% from 66-67% previously.

Piper Sandler indicated the quarterly results may help address bearish concerns about the durability of U.S. procedure growth, potential softening in the capital environment, and margin pressures.

The research firm expressed confidence in Intuitive Surgical’s performance, stating the company is "set up well for a strong 2026 campaign" following the encouraging third-quarter results.

In other recent news, Intuitive Surgical reported impressive third-quarter results, with revenue reaching $2.505 billion, marking a 22.9% increase year-over-year. The company’s adjusted earnings per share came in at $2.40, surpassing BTIG’s expectations of $1.85. Worldwide sales exceeded consensus by 4%, while da Vinci procedure growth reached 19% year-over-year, compared to the anticipated 15.8%. Following these results, several analyst firms adjusted their price targets for Intuitive Surgical. RBC Capital raised its price target to $625, emphasizing the company’s strong performance, with sales and earnings per share exceeding forecasts by 4% and 20%, respectively. Leerink Partners also increased its price target to $600, maintaining an Outperform rating. BTIG adjusted its price target to $589, while Evercore ISI raised its target to $540, citing the company’s broad-based performance improvements. Bernstein reiterated its Outperform rating with a price target of $685, highlighting strong system placements and procedure volumes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.